{"id":"prame","name":"PRAME","symbol":"PRAME","route":"/targets/prame/","asOf":"2026-09-07","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9336","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185686","uniprot":"https://www.uniprot.org/uniprotkb/P78395/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P78395","open-targets":"https://platform.opentargets.org/target/ENSG00000185686","civic":"https://civicdb.org/genes/23532/summary","oncokb":"https://www.oncokb.org/gene/PRAME","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PRAME","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=PRAME","depmap":"https://depmap.org/portal/gene/PRAME?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000185686-PRAME","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/23532","omim":"https://www.omim.org/entry/606021"}],"products":[{"id":"brenetafusp","name":"Brenetafusp","status":"phase-3","modality":"ImmTAC (PRAME TCR × CD3 bispecific)","route":"/drugs/brenetafusp/"},{"id":"ima203","name":"IMA203","status":"phase-3","modality":"TCR-T cell therapy","route":"/drugs/ima203/"}],"trials":[{"id":"prism-mel-301","name":"PRISM-MEL-301","nct":"NCT06112314","phase":"3","status":"recruiting"},{"id":"nct06743126","name":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","nct":"NCT06743126","phase":"3","status":"recruiting"},{"id":"nct05958121","name":"IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors","nct":"NCT05958121","phase":"1/2","status":"recruiting"},{"id":"nct04262466","name":"Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors","nct":"NCT04262466","phase":"1/2","status":"active"}],"pathways":[],"companies":["immatics","immunocore"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}